Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study.
about
The role of preoperative systemic treatment in patients with breast cancerSystemic treatment strategies for triple-negative breast cancer.Paclitaxel, carboplatin, and trastuzumab in a neo-adjuvant regimen for HER2-positive breast cancer.Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40A phase II trial of dose-dense (biweekly) paclitaxel plus carboplatin as neoadjuvant chemotherapy for operable breast cancer.Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapyNew Insights in the Cytogenetic Practice: Karyotypic Chaos, Non-Clonal Chromosomal Alterations and Chromosomal Instability in Human Cancer and Therapy ResponsePhase II trial of neoadjuvant weekly nanoparticle albumin-bound paclitaxel, carboplatin, and biweekly bevacizumab therapy in women with clinical stage II or III HER2-negative breast cancerOut of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinomaPaclitaxel, Carboplatin, and trastuzumab.Management options in triple-negative breast cancerTips and tricks in triple-negative breast cancer: how to manage patients in real-life practice?Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer.Pathologic complete response rates in triple-negative, HER2-positive, and hormone receptor-positive breast cancers after anthracycline-free neoadjuvant chemotherapy with carboplatin and paclitaxel with or without trastuzumab.A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancerA DNA repair BRCA1 estrogen receptor and targeted therapy in breast cancer.Preoperative concurrent paclitaxel-radiation in locally advanced breast cancer: pathologic response correlates with five-year overall survival.Weekly paclitaxel/carboplatin/trastuzumab therapy improves pathologic complete remission in aggressive HER2-positive breast cancers, especially in luminal-B subtype, compared with a once-every-3-weeks schedule.Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer.Neoadjuvant therapy in operable breast cancer: application to triple negative breast cancer.Current approaches for neoadjuvant chemotherapy in breast cancer.Host Cell Reactivation and Transcriptional Activation of Carboplatin-Modified BRCA1.Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy.Neoadjuvant systemic treatment of breast cancer.Systemic treatment of early breast cancer--a biological perspective.The paradox of triple negative breast cancer: novel approaches to treatment.A multicenter, phase II study of epirubicin/cyclophosphamide followed by docetaxel and concurrent trastuzumab as primary systemic therapy for HER-2 positive advanced breast cancer (the HER2NAT study).Neoadjuvant treatments for triple-negative breast cancer (TNBC).Primary systemic therapy in HER2-amplified breast cancer: a clinical review.Primary therapy in breast cancer: what have we learned from landmark trials?Triple-negative breast cancer possibly transforming into malignant melanoma due to targeted therapy? A case report and review of literature.The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis.Assessing the role of platinum agents in aggressive breast cancers.Neoadjuvant Chemotherapy In Triple-Negative Breast Cancer: A Multicentric Retrospective Observational Study In Real-Life Setting.Neoadjuvant Chemotherapy with Docetaxel, Carboplatin and Weekly Trastuzumab Is Active in HER2-Positive Early Breast Cancer: Results after a Median Follow-Up of over 4 Years.CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer.Predictive factors of pathologic complete response in HER2-positive and axillary lymph node positive breast cancer after neoadjuvant paclitaxel, carboplatin plus with trastuzumab.Unfavorable pathological complete response rate of neoadjuvant chemotherapy epirubicin plus taxanes for locally advanced triple-negative breast cancer.Cisplatin versus carboplatin in combination with paclitaxel as neoadjuvant regimen for triple negative breast cancer.Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results.
P2860
Q26746034-0185CA95-803E-444A-BE15-9B4F377B4CABQ27691414-7732CFEF-573D-4946-8D1E-71F19B76AFB5Q33407805-05E2546A-2D5E-4C42-A928-545A222F164FQ33416887-84A171D4-8267-42F5-9A8F-AC62BE0D9787Q33430463-A26EE9AC-0765-4407-BC61-2286105AFE0BQ33573055-AD328071-3818-4A6D-BC6C-9077A3EB4343Q33836777-A023CFAA-22DC-441E-AF2E-BCF0DAB732FDQ33922971-77F121CE-1FB2-4C96-B3D8-0E7D9CAC7F3CQ34064466-34AB5D14-EFBE-4D43-AFE5-46E1339B3C9CQ34612916-C0627FB2-F33D-43A9-AEAB-3AD608A690C1Q35155460-4C702656-2C63-4F76-9A67-6B5CA5DFD0F5Q35572763-86A3E0DF-3624-43BF-97A3-C42971856EE1Q35742760-3F48C390-DC81-4436-8457-27E8761BA6E4Q36132952-DEA7A3B0-7677-4F6A-BED3-0DD43006C5D4Q36204215-0F05F36E-1085-4134-8B0A-A9ED10709589Q36432567-C6D4D66A-BAFF-4F7A-AEBC-554B9C23DDDDQ36848102-16B06798-E478-428E-AC82-371870F6FC31Q36871664-A91AD780-F65E-41BD-A97C-D41BB874D4EFQ36917231-83B46708-654D-43CF-ABBF-F3CD94785D75Q37105085-506E1D09-AF75-4409-9DE7-E033857F841EQ37135365-59318434-F9FA-4499-9FEF-A88C2F928342Q37660257-0AA37AD1-EE08-4275-8C6E-666953AD6D05Q37835104-9B3D43F4-E274-4CC4-A9E4-FD79BD25C6AAQ37845317-A5FA78EA-3B30-4FE2-B0B0-0E2822A595CAQ37863638-A8EC44BD-1BA8-4BE2-A466-3ECFE322407BQ37958063-ABA4006F-41F8-4455-B3FE-059D5FEB9201Q38029563-5F082564-07D0-4B78-A6AE-C6D0EB438E99Q38046580-A9D6AD2B-57B9-484B-928C-97936316EF75Q38048814-B5570731-B06F-4DE6-A9B1-9EB772C27AB8Q38155673-72263D4B-6FB5-457A-A2CC-B4E16011B5EDQ38162093-58FA8E8F-D59F-46F5-859F-60C5C6EE4A5DQ38190005-F180DF78-A326-4194-A974-0D705E85B17EQ38349378-A18EA7B7-260F-4D41-93E6-CAAB36C62ACEQ38677841-8B962367-D1C5-4094-9F8D-BA953DE8EBEEQ39128135-24CA9F15-9891-4BA4-85D7-F3091BB4CD63Q39465495-BBBACA99-0DAD-4E2C-9915-14D5685E86B6Q41345524-9C406365-2E83-4561-B5B5-36502E348205Q45004261-DA09C8E7-5252-403D-B4ED-448F851A08F3Q47101500-1B6A3BEA-E2B3-4028-AAE6-F9838B2130D5Q47788774-8DCB2278-CC5F-43A4-A644-0A49D2020C0A
P2860
Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study.
description
2009 nî lūn-bûn
@nan
2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Frequent pathologic complete r ...... iversity Oncology Group Study.
@ast
Frequent pathologic complete r ...... iversity Oncology Group Study.
@en
type
label
Frequent pathologic complete r ...... iversity Oncology Group Study.
@ast
Frequent pathologic complete r ...... iversity Oncology Group Study.
@en
prefLabel
Frequent pathologic complete r ...... iversity Oncology Group Study.
@ast
Frequent pathologic complete r ...... iversity Oncology Group Study.
@en
P2093
P356
P1476
Frequent pathologic complete r ...... iversity Oncology Group Study.
@en
P2093
Don S Dizon
Jennifer S Gass
Kathy P Theall
Mary Anne Fenton
Robert D Legare
Rochelle Strenger
Teresa A Kennedy
Theresa A Graves
William M Sikov
P304
P356
10.1200/JCO.2008.21.4163
P407
P577
2009-08-31T00:00:00Z